Literature DB >> 17070077

T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.

Elke Valk1, Rufina Leung, Hyun Kang, Kazuyo Kaneko, Christopher E Rudd, Helga Schneider.   

Abstract

The costimulatory molecule CTLA-4 is a potent downregulator of T cell responses. Although localized mostly in intracellular compartments, little is understood regarding the mechanism that regulates its transport to the cell surface. In this study, we demonstrated that the adaptor TRIM (T cell receptor-interacting molecule) bound to CTLA-4 in the trans Golgi network (TGN) and promoted transport of CTLA-4 to the surface of T cells. Increased TRIM expression augmented surface CTLA-4 expression, and pulse-chase analysis showed a more rapid transport of CTLA-4 to the cell surface. A reduction of TRIM expression by small hairpin RNAs reduced the expression of surface CTLA-4. This resulted in a more localized pattern of CTLA-4 in the TGN. Altered CTLA-4 expression by TRIM was accompanied by corresponding changes in coreceptor-mediated effects on cytokine production and proliferation. Our findings identify a role for TRIM as a chaperone in regulating CTLA-4 expression and function by enhancing CTLA-4 transport to the surface of T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070077     DOI: 10.1016/j.immuni.2006.08.024

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  27 in total

Review 1.  T-cell costimulatory blockade in organ transplantation.

Authors:  Jonathan S Maltzman; Laurence A Turka
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

Review 2.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

3.  Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4.

Authors:  Seng-Ryong Woo; Nianyu Li; Tullia C Bruno; Karen Forbes; Scott Brown; Creg Workman; Charles G Drake; Dario A A Vignali
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

Review 4.  At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Authors:  Andrew M Intlekofer; Craig B Thompson
Journal:  J Leukoc Biol       Date:  2013-04-26       Impact factor: 4.962

Review 5.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

Review 6.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

7.  Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal.

Authors:  Yuning Lu; Helga Schneider; Christopher E Rudd
Journal:  Blood       Date:  2012-10-09       Impact factor: 22.113

8.  Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4.

Authors:  Xuan Mo; Hanghang Zhang; Sarah Preston; Kayla Martin; Bo Zhou; Nish Vadalia; Ana M Gamero; Jonathan Soboloff; Italo Tempera; M Raza Zaidi
Journal:  Cancer Res       Date:  2017-11-17       Impact factor: 12.701

9.  Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.

Authors:  Matthieu Sawaf; Jean-Daniel Fauny; Renaud Felten; Flora Sagez; Jacques-Eric Gottenberg; Hélène Dumortier; Fanny Monneaux
Journal:  JCI Insight       Date:  2018-07-12

Review 10.  CD28 and CTLA-4 coreceptor expression and signal transduction.

Authors:  Christopher E Rudd; Alison Taylor; Helga Schneider
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.